Interestingly, Pdx1-Cre-K-MADM-p53 mice exhibited a median survival of ∼11 weeks, falling in between that observed in Pdx1-Cre; LSL-KrasG12D/KrasWT (KC) mice harbouring homozygous p53 mutation (∼6 weeks) and heterozygous p53 mutation (∼16 weeks) (Fig. 5g), supporting p53 LOH as an important driver of tumour progression in this model. Here, TP53 is linked to neoplasm.